Home Banking & Finance Greenburgh company makes biotech stock index

Greenburgh company makes biotech stock index

SHARE

Progenics Pharmaceuticals Inc. in Greenburgh on Monday was added to the NASDAQ Biotechnology Index.

The index tracks the performance of a set of securities listed on the NASDAQ stock market that are classified by industry as either biotechnology or pharmaceuticals.  It is a modified market capitalization weighted index. Companies must meet eligibility criteria that include a market capitalization of at least $200 million and average daily trading volume of at least 100,000 shares.

Index stocks are evaluated semiannually in May and November and serve as the basis for the iShares NASDAQ Biotechnology Index Fund, which seeks investment results that correspond generally to price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. Options based on the NASDAQ Biotechnology Index and the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.

Headquartered on the Landmark at Eastview life sciences campus, Progenics Pharmaceuticals Inc. develops drugs for oncology. Its first commercial product, Relistor, is used to treat for opioid-induced constipation in terminally ill cancer patients.

 

 

 

 

 

 

Print Friendly, PDF & Email
Previous articleStarwood partners with NRG Energy on solar systems
Next articleApp promotes black-owned businesses
As managing editor of the Business Journals, John Golden directs news coverage of Westchester and Fairfield counties and the Hudson Valley region. He was an award-winning upstate columnist and feature writer before joining the Business Journal in 2007. He is the author of “Northern Drift: Sketches on the New York Frontier,” a collection of his regional journalism.

LEAVE A REPLY

Please enter your comment!
Please enter your name here